Fig. 3.

HBV kinetics and model (Eqs (1), (2), (3)) fit curves in PHHs treated with ETV and/or Myrcludex (Myr-preS1) for 12 days.

(A) ETV-treated PHHs, (B) Myr-PreS1-treated PHHs, and (C) ETV + Myr-preS1-treated PHHs. There are three samples measured at each time point. Lines represent model best fits corresponding to Eqs (1), (2), (3). The beginning of cccDNA amplification after the time of HBV inoculation is estimated as 22 h (parameter S₀ in Table 1). The drop in extracellular HBV DNA at time points 1, 2, and 7 replicates the replenishment at Days 1, 2, and 7, respectively. Parameter values are shown in Table 1. Note that for (A) and (C), parameters S₀, σ_max, C_max, τ, p_max, κ_max, μ, ν, and τ₁ were fixed based on their values from (B). ETV, entecavir; Myr-preS1, myristoylated pre-S/2-48myr peptide; PHH, primary human hepatocyte.